The case for adjuvant chemotherapy in pancreatic cancer

P Ghaneh, A Sultana, S Shore, Deborah Stocken, J Neoptolemos

Research output: Contribution to journalArticle

16 Citations (Scopus)


Pancreatic cancer is a difficult cancer to treat effectively. Only a small proportion of patients are suitable for resection. The long-term survival following resection alone is between 10 and 18%. Adjuvant therapy aims to improve this outcome. There have been five fully reported adjuvant trials in pancreatic cancer. The largest study is the ESPAC-1 trial which demonstrated a significant survival benefit for 5-fluorouracil chemotherapy and no survival benefit for adjuvant chemoradiotherapy. A meta-analysis of these trials has confirmed the survival benefit for chemotherapy and thus adjuvant chemotherapy is recommended as the standard of care following pancreatic resection. There are further large studies which will also help to further define the optimum adjuvant chemotherapy in these patients.
Original languageEnglish
Pages (from-to)383-401
Number of pages19
JournalBest Practice & Research: Clinical Gastroenterology
Publication statusPublished - 1 Apr 2006


Dive into the research topics of 'The case for adjuvant chemotherapy in pancreatic cancer'. Together they form a unique fingerprint.

Cite this